<abstract xmlns="http://www.w3.org/1999/xhtml"><sec id="j_fco-2018-0005_s_006_w2aab3b7b3b1b6b1aab1c17b1Aa"><h3>Introduction</h3><p>Several studies show that mutational profiles could influence treatment decisions in patients with metastatic CRC (mCRC). <italic>KRAS</italic> mutational status was the first step in biomarkers development in the era of molecular targeted therapies. Recently, NRAS mutational status was identified as an independent prognostic factor for the response to treatment with anti-EGFR moAbs. The aim of this observational study was to assess the feasibility of the KRAS/NRAS mutational analysis in patients with metastatic colorectal cancer in Greece and to identify any correlations with known clinical characteristics and histopathologic features.</p></sec><sec id="j_fco-2018-0005_s_007_w2aab3b7b3b1b6b1aab1c17b2Aa"><h3>Methods</h3><p>From January 2014 until September 2014 all patients registered to the GIC-SG database with newly diagnosed metastatic disease from colon or rectal cancer were included and tumor samples were analyzed for kras/nras mutations in 9 different certified laboratories in Greece.</p></sec><sec id="j_fco-2018-0005_s_008_w2aab3b7b3b1b6b1aab1c17b3Aa"><h3>Results</h3><p>Samples from 510 patients were analyzed. Mutations’ distribution was as follows: 173 (33,9%) <italic>KRAS</italic> exon 2, 10 (2%) <italic>KRAS</italic> exon 3, 25 (4,9%) <italic>KRAS</italic> exon 4, 22 (4,3%) <italic>NRAS</italic> exon 2, 11 (2,2%) <italic>NRAS</italic> exon 3 and 3 (0,6%) <italic>NRAS</italic> exon 4. The only factor significantly associated with <italic>RAS</italic> mutational status was primary tumor location, with right sided tumors exhibiting higher rates of mutations.</p></sec><sec id="j_fco-2018-0005_s_009_w2aab3b7b3b1b6b1aab1c17b4Aa"><h3>Discussion</h3><p>The incidence and distribution of <italic>KRAS</italic> or <italic>NRAS</italic> exon 2-4 mutations are in accordance with those reported in the literature. The most significant clinical or pathological parameter revealed from the analysis is the location of the primary tumor.</p></sec></abstract>

IntroductionSeveral studies show that mutational profiles could influence treatment decisions in patients with metastatic CRC (mCRC). KRAS mutational status was the first step in biomarkers development in the era of molecular targeted therapies. Recently, NRAS mutational status was identified as an independent prognostic factor for the response to treatment with anti-EGFR moAbs. The aim of this observational study was to assess the feasibility of the KRAS/NRAS mutational analysis in patients with metastatic colorectal cancer in Greece and to identify any correlations with known clinical characteristics and histopathologic features.MethodsFrom January 2014 until September 2014 all patients registered to the GIC-SG database with newly diagnosed metastatic disease from colon or rectal cancer were included and tumor samples were analyzed for kras/nras mutations in 9 different certified laboratories in Greece.ResultsSamples from 510 patients were analyzed. Mutations’ distribution was as follows: 173 (33,9%) KRAS exon 2, 10 (2%) KRAS exon 3, 25 (4,9%) KRAS exon 4, 22 (4,3%) NRAS exon 2, 11 (2,2%) NRAS exon 3 and 3 (0,6%) NRAS exon 4. The only factor significantly associated with RAS mutational status was primary tumor location, with right sided tumors exhibiting higher rates of mutations.DiscussionThe incidence and distribution of KRAS or NRAS exon 2-4 mutations are in accordance with those reported in the literature. The most significant clinical or pathological parameter revealed from the analysis is the location of the primary tumor.

Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)

Forum of Clinical Oncology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

IntroductionSeveral studies show that mutational profiles could influence treatment decisions in patients with metastatic CRC (mCRC). KRAS mutational status...

Feature		Patients #	%
Gender		510	100
	Male	329	65
	Female	181	35
Tumor Location
	Right Colon	169	33
	Left Colon	215	42
	Rectum	126	25
Tumor Differentiation
	Well/Moderate	323	63
	Undifferentiated	112	22
	Unknown	74	14
Mucinous	Yes	351	69
	No	85	17
	Unknown	74	14
Metastatic sites
	Liver	379	74
	Lung	193	38
	Peritoneum	98	19
Mutation
	Present	244	48
	Undetectable	256	52

Feature No (%)			RAS mutation		p value

		Total	Wild Type	Mutant
	≤ 70 years	380 (75)	203 (53.4)	177 (46.6)
Age	> 70 years	130 (25)	63 (48.5)	67 (51.5)	0.360
	Low grade	323 (74)	159 (49.2)	164 (50.8)
Tumor Differentiation	High grade	112 (26)	60 (53.6)	52 (46.4)	0.444
	Right	169 (33)	108 (63.9)	61 (36.9)
Tumor Location	Left	341 (67)	136 (39.9)	205 (77.1)	<0.001
	Yes	85 (17)	49 (57.6)	36 (42.4)
Mucinous	No	351 (83)	173 (49.3)	178 (50.7)	0.187
	Male	389 (65)	148 (45)	181(55)
Gender	Female	181 (35)	96 (53)	85 (45)	0.095

Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)

Article Category: Research Article

Publié en ligne: 12 juil. 2019

Pages: 31 - 36

Reçu: 22 mars 2018

Accepté: 17 mars 2019

DOI: https://doi.org/10.2478/fco-2018-0005

Mots clés
KRAS-NRAS mutation, colorectal cancer, metastatic disease

© 2018 Nikolaos Gouvas, Telenia Kalambaliki, Alexandra Voutsina, Zenia Saridaki, Maria Tzardi, Aristea Kalykaki, Maria Sfakianaki, Athanasios Athanasiadis, Evaghelos Xynos, Ioannis Boukovinas, John Souglakos, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Figure 2

Patients and disease characteristics.

Correlation of RAS mutation with clinical and pathological characteristics.

Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)

Article Category: Research Article

Publié en ligne: 12 juil. 2019

Pages: 31 - 36

Reçu: 22 mars 2018

Accepté: 17 mars 2019

DOI: https://doi.org/10.2478/fco-2018-0005

Mots clésKRAS-NRAS mutation, colorectal cancer, metastatic disease

© 2018 Nikolaos Gouvas, Telenia Kalambaliki, Alexandra Voutsina, Zenia Saridaki, Maria Tzardi, Aristea Kalykaki, Maria Sfakianaki, Athanasios Athanasiadis, Evaghelos Xynos, Ioannis Boukovinas, John Souglakos, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Figure 2

Patients and disease characteristics.

Correlation of RAS mutation with clinical and pathological characteristics.

Mots clés
KRAS-NRAS mutation, colorectal cancer, metastatic disease